Gabri van der Pluijm

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3042221/publications.pdf

Version: 2024-02-01

50 papers	2,591 citations	185998 28 h-index	214527 47 g-index
50 all docs	50 docs citations	50 times ranked	4333 citing authors

#	Article	IF	Citations
1	Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer models. Cancer Gene Therapy, 2022, 29, 793-802.	2.2	7
2	Nonhuman Primate Adenoviruses of the Human Adenovirus B Species Are Potent and Broadly Acting Oncolytic Vector Candidates. Human Gene Therapy, 2022, 33, 275-289.	1.4	7
3	Patient-derived tumour models for personalized therapeutics in urological cancers. Nature Reviews Urology, 2021, 18, 33-45.	1.9	19
4	The Identification of Small Molecule Inhibitors That Reduce Invasion and Metastasis of Aggressive Cancers. International Journal of Molecular Sciences, 2021, 22, 1688.	1.8	1
5	Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer. Oncogene, 2021, 40, 3087-3100.	2.6	18
6	An exploratory firstâ€inâ€man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2â€•and 1â€•week interval in patients with metastatic castration resistant prostate cancer. Pharmacology Research and Perspectives, 2021, 9, e00845.	1.1	2
7	Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dyeâ€“Protein Interaction. Journal of Nuclear Medicine, 2020, 61, 234-241.	2.8	42
8	Cationic amphiphilic drugs as potential anticancer therapy for bladder cancer. Molecular Oncology, 2020, 14, 3121-3134.	2.1	6
9	Developing oncolytic viruses for clinical use: A consortium approach. Cytokine and Growth Factor Reviews, 2020, 56, 133-140.	3.2	13
10	Systematic evaluation of design features enables efficient selection of Î electron-stabilized polymeric micelles. International Journal of Pharmaceutics, 2020, 584, 119409.	2.6	11
11	The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice. Journal of Thrombosis and Haemostasis, 2019, 17, 951-963.	1.9	18
12	Oncolytic activity of the rhabdovirus VSVâ€GP against prostate cancer. International Journal of Cancer, 2018, 143, 1786-1796.	2.3	29
13	The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy. Clinical Cancer Research, 2018, 24, 927-938.	3.2	128
14	An ex vivo Tissue Culture Model for the Assessment of Individualized Drug Responses in Prostate and Bladder Cancer. Frontiers in Oncology, 2018, 8, 400.	1.3	44
15	Osteolytic cancer cells induce vascular/axon guidance processes in the bone/bone marrow stroma. Oncotarget, 2018, 9, 28877-28896.	0.8	9
16	Transplantable Animal Studies and Whole-Body Optical Imaging in Prostate Carcinoma. Methods in Molecular Biology, 2018, 1786, 81-102.	0.4	0
17	Protocols for Migration and Invasion Studies in Prostate Cancer. Methods in Molecular Biology, 2018, 1786, 67-79.	0.4	43
18	Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patientâ€derived xenograft (PDX) models. Prostate, 2018, 78, 1262-1282.	1.2	76

#	Article	IF	Citations
19	ALK1Fc Suppresses the Human Prostate Cancer Growth in in Vitro and in Vivo Preclinical Models. Frontiers in Cell and Developmental Biology, 2017, 5, 104.	1.8	3
20	Spontaneous development of Epstein-Barr Virus associated human lymphomas in a prostate cancer xenograft program. PLoS ONE, 2017, 12, e0188228.	1.1	16
21	Development of a Patient-Derived Xenograft (PDX) of Breast Cancer Bone Metastasis in a Zebrafish Model. International Journal of Molecular Sciences, 2016, 17, 1375.	1.8	78
22	Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model. Biology Open, 2016, 6, 133-140.	0.6	11
23	Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer. Trends in Pharmacological Sciences, 2016, 37, 451-462.	4.0	45
24	The role of microRNAs in bone metastasis. Journal of Bone Oncology, 2016, 5, 104-108.	1.0	32
25	XRP44X, an Inhibitor of Ras/Erk Activation of the Transcription Factor Elk3, Inhibits Tumour Growth and Metastasis in Mice. PLoS ONE, 2016, 11, e0159531.	1.1	17
26	Epithelial Plasticity in Cancer: Unmasking a MicroRNA Network for TGF-Î²-, Notch-, and Wnt-Mediated EMT. Journal of Oncology, 2015, 2015, 1-13.	0.6	39
27	Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth In Vivo. Prostate, 2015, 75, 815-824.	1.2	41
28	SYK Is a Candidate Kinase Target for the Treatment of Advanced Prostate Cancer. Cancer Research, 2015, 75, 230-240.	0.4	61
29	miR-25, integrin and cancer invasiveness. Oncoscience, 2015, 2, 663-664.	0.9	3
30	Targeting of Alpha-V Integrins Reduces Malignancy of Bladder Carcinoma. PLoS ONE, 2014, 9, e108464.	1.1	35
31	The Molecular Signature of the Stroma Response in Prostate Cancer-Induced Osteoblastic Bone Metastasis Highlights Expansion of Hematopoietic and Prostate Epithelial Stem Cell Niches. PLoS ONE, 2014, 9, e114530.	1.1	42
32	Liposomal nanomedicines in the treatment of prostate cancer. Cancer Treatment Reviews, 2014, 40, 578-584.	3.4	48
33	Glycogen synthase kinase-3Î² inhibition depletes the population of prostate cancer stem/progenitor-like cells and attenuates metastatic growth. Oncotarget, 2014, 5, 8986-8994.	0.8	40
34	Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness. Oncotarget, 2014, 5, 7357-7367.	0.8	24
35	Epithelial Plasticity, Cancer Stem Cells, and the Tumor-Supportive Stroma in Bladder Carcinoma. Molecular Cancer Research, 2012, 10, 995-1009.	1.5	142
36	Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone, 2011, 48, 37-43.	1.4	130

#	Article	IF	Citations
37	Real-Time Cancer Cell Tracking by Bioluminescence in a Preclinical Model of Human Bladder Cancer Growth and Metastasis. European Urology, 2011, 60, 337-343.	0.9	48
38	The aldehyde dehydrogenase enzyme 7A1 is functionally involved in prostate cancer bone metastasis. Clinical and Experimental Metastasis, 2011, 28, 615-625.	1.7	90
39	High Aldehyde Dehydrogenase Activity Identifies Tumor-Initiating and Metastasis-Initiating Cells in Human Prostate Cancer. Cancer Research, 2010, 70, 5163-5173.	0.4	351
40	Prostate cancer cells home to bone in a new in vivo model of bone metastasis. FASEB Journal, 2009, 23, 927.11.	0.2	1
41	Advances in optical imaging and novel model systems for cancer metastasis research. Clinical and Experimental Metastasis, 2007, 24, 699-705.	1.7	50
42	TGF-Î² and BMP7 interactions in tumour progression and bone metastasis. Clinical and Experimental Metastasis, 2007, 24, 609-617.	1.7	111
43	Interference with the Microenvironmental Support Impairs the De novo Formation of Bone Metastases In vivo. Cancer Research, 2005, 65, 7682-7690.	0.4	116
44	In Vitro and in Vivo Endochondral Bone Formation Models Allow Identification of Anti-Angiogenic Compounds. American Journal of Pathology, 2003, 163, 157-163.	1.9	8
45	MÃ©canismes impliquÃ©s dans lâ€™invasion de lâ€™os par les cellules tumorales. Revue Du Rhumatisme (Edition) Tj ETQq1 1 0.78	0.0	0
46	Urokinase-Receptor/Integrin Complexes Are Functionally Involved in Adhesion and Progression of Human Breast Cancer in Vivo. American Journal of Pathology, 2001, 159, 971-982.	1.9	97
47	Monitoring Metastatic Behavior of Human Tumor Cells in Mice with Speciesâ€Specific Polymerase Chain Reaction: Elevated Expression of Angiogenesis and Bone Resorption Stimulators by Breast Cancer in Bone Metastases. Journal of Bone and Mineral Research, 2001, 16, 1077-1091.	3.1	117
48	Effect of Angiogenic and Antiangiogenic Compounds on the Outgrowth of Capillary Structures from Fetal Mouse Bone Explants. Laboratory Investigation, 2001, 81, 5-15.	1.7	54
49	Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton. Cancer, 2000, 88, 3047-3053.	2.0	52
50	The Role of Geranylgeranylation in Bone Resorption and Its Suppression by Bisphosphonates in Fetal Bone Explants In Vitro: A Clue to the Mechanism of Action of Nitrogen-Containing Bisphosphonates. Journal of Bone and Mineral Research, 1999, 14, 722-729.	3.1	216